{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:14:43Z","timestamp":1783703683466,"version":"3.55.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Heparin-induced thrombocytopenia (HIT) is a life or limb-threatening thrombotic thrombocytopenia. HIT is traditionally treated with factor-IIa inhibitors such as bivalirudin, lepirudin, or argatroban. However, these agents usually require parenteral administration and are not generally available in all countries. Recently, several experiences with novel oral anticoagulants (NOACs) administration to treat HIT had been reported. NOACs generally offer advantages such as consistent and predictable anticoagulation, oral administration with good patient compliance, and a good safety profile. We report a case of HIT with severe thrombotic complications successfully treated with rivaroxaban and discuss the current knowledge about the use of NOACs for the treatment of this potentially fatal thrombocytopenia.<\/jats:p>","DOI":"10.1097\/fjc.0000000000000421","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T23:50:18Z","timestamp":1469663418000},"page":"391-394","source":"Crossref","is-referenced-by-count":14,"title":["Heparin-induced Thrombocytopenia Presenting With Deep Venous Thrombosis and Pulmonary Embolism Successfully Treated With Rivaroxaban: Clinical Case Report and Review of Current Experiences"],"prefix":"10.1097","volume":"68","author":[{"given":"Matej","family":"Samo\u0161","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic;"},{"name":"Division of Molecular Medicine, BioMed Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Bolek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jela","family":"Ivankov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, National Center of Hemostasis and Thrombosis, Comenius University in Bratislava, Martin, Slovak Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Stan\u010diakov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, National Center of Hemostasis and Thrombosis, Comenius University in Bratislava, Martin, Slovak Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franti\u0161ek","family":"Kov\u00e1\u0159","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Galajda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kubisz","sequence":"additional","affiliation":[{"name":"Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, National Center of Hemostasis and Thrombosis, Comenius University in Bratislava, Martin, Slovak Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1n","family":"Sta\u0161ko","sequence":"additional","affiliation":[{"name":"Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, National Center of Hemostasis and Thrombosis, Comenius University in Bratislava, Martin, Slovak Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00e1n","family":"Mok\u00e1\u0148","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230911","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11239-011-0569-6","article-title":"Heparin-induced thrombocytopenia: present and future","volume":"31","author":"Cuker","year":"2011","journal-title":"J Thromb Thrombolysis."},{"key":"R2-20230911","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/187152907781745251","article-title":"Heparin induced thrombocytopenia: pathogenetic, clinical, diagnostic and therapeutic aspects","volume":"7","author":"Castelli","year":"2007","journal-title":"Cardiovasc Hematol Disord Drug Targets."},{"key":"R3-20230911","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood-2011-11-376293","article-title":"How I treat heparin-induced thrombocytopenia","volume":"119","author":"Cuker","year":"2012","journal-title":"Blood"},{"key":"R4-20230911","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/MOH.0b013e32833c07a7","article-title":"Treatment options in heparin-induced thrombocytopenia","volume":"17","author":"Hook","year":"2010","journal-title":"Curr Opin Hematol."},{"key":"R5-20230911","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.jtcvs.2015.04.054","article-title":"Rivaroxaban for treatment of heparin-induced thrombocytopenia after cardiac surgery: a case report","volume":"150","author":"Abouchakra","year":"2015","journal-title":"J Thorac Cardiovasc Surg."},{"key":"R6-20230911","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s11239-015-1208-4","article-title":"Rivaroxaban in the treatment of heparin-induced thrombocytopenia","volume":"40","author":"Sartori","year":"2015","journal-title":"J Thromb Thrombolysis."},{"key":"R7-20230911","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/MBC.0000000000000205","article-title":"Rivaroxaban for arterial thrombosis related to heparin-induced thrombocytopenia","volume":"26","author":"Hantson","year":"2015","journal-title":"Blood Coagul Fibrinolysis."},{"key":"R8-20230911","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.thromres.2014.06.005","article-title":"First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia","volume":"135","author":"Ng","year":"2015","journal-title":"Thromb Res."},{"key":"R9-20230911","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/ccr3.411","article-title":"Apixaban used for the management of heparin-induced thrombocytopenia in a 72-year-old woman with lung cancer","volume":"3","author":"Larsen","year":"2015","journal-title":"Clin Case Rep."},{"key":"R10-20230911","first-page":"112","article-title":"Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia","volume":"9","author":"Mirdamadi","year":"2013","journal-title":"ARYA Atheroscler."},{"key":"R11-20230911","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1345\/aph.1Q474","article-title":"Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies","volume":"46","author":"Fieland","year":"2012","journal-title":"Ann Pharmacother."},{"key":"R12-20230911","doi-asserted-by":"crossref","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"key":"R13-20230911","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMct1206642","article-title":"Nonheparin anticoagulants for heparin-induced thrombocytopenia","volume":"368","author":"Kelton","year":"2013","journal-title":"N Engl J Med."},{"key":"R14-20230911","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ejh.12179","article-title":"Fondaparinux-associated heparin-induced thrombocytopenia","volume":"91","author":"Bhatt","year":"2013","journal-title":"Eur J Haematol."},{"key":"R15-20230911","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med."},{"key":"R16-20230911","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med."},{"key":"R17-20230911","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med."},{"key":"R18-20230911","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/187152571302151217124551","article-title":"New oral anticoagulants for the management of heparin induced thrombocytopenia: a focused literature review","volume":"13","author":"Dhakal","year":"2015","journal-title":"Cardiovasc Hematol Agents Med Chem."},{"key":"R19-20230911","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1160\/TH14-07-0593","article-title":"Delayed-onset heparin-induced thrombocytopenia without thrombosis in a patient receiving postoperative thromboprophylaxis with rivaroxaban","volume":"114","author":"Tardy-Poncet","year":"2015","journal-title":"Thromb Haemost."},{"key":"R20-20230911","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11239-014-1064-7","article-title":"Design of the rivaroxaban for heparin-induced thrombocytopenia study","volume":"38","author":"Linkins","year":"2014","journal-title":"J Thromb Thrombolysis"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005344-201611000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T01:12:18Z","timestamp":1694394738000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005344-201611000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0000000000000421","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}